about
Metal pollutants and cardiovascular disease: mechanisms and consequences of exposureDuration of anticoagulation for venous thromboembolic eventsPeriprocedural glycemic control in patients with diabetes mellitus undergoing coronary angiography with possible percutaneous coronary intervention.Diabetes and vascular disease in different arterial territories.Proatherogenic oxidized low-density lipoprotein/β2-glycoprotein I complexes in arterial and venous disease.Hyperglycemia enhances arsenic-induced platelet and megakaryocyte activation.Association Between Anemia, Bleeding, and Transfusion with Long-term Mortality Following Noncardiac Surgery.Underuse of Prevention and Lifestyle Counseling in Patients With Peripheral Artery Disease.The Effect of Previous Resident Interactions on the Assessment of Interpersonal and Communication Skills by Teaching Faculty: Are We the Best Evaluators?Intravenous heparin dosing strategy in hospitalized patients with atrial dysrhythmias.The assessment of thrombotic markers utilizing ionic versus non-ionic contrast during coronary angiography and intervention trial.Greater Frequency of Fruit and Vegetable Consumption Is Associated With Lower Prevalence of Peripheral Artery Disease.Neutrophil-derived S100 calcium-binding proteins A8/A9 promote reticulated thrombocytosis and atherogenesis in diabetes.Platelet-Derived MRP-14 Induces Monocyte Activation in Patients With Symptomatic Peripheral Artery Disease.Changes in High-Density Lipoprotein Cholesterol Efflux Capacity After Bariatric Surgery Are Procedure Dependent.Lipoprotein(a) screening in patients with controlled traditional risk factors undergoing percutaneous coronary intervention.The AAMC Medical Student Performance Evaluation Task Force Recommendations: Do They Go Far Enough?Changes in lipoprotein(a) following bariatric surgery.Antithrombotic therapy in peripheral artery disease.Heparin-induced thrombocytopenia (HIT): Review of incidence, diagnosis, and managementPlatelet regulation of myeloid suppressor of cytokine signaling 3 accelerates atherosclerosisCardiovascular Outcomes of Patients With Pulmonary Hypertension Undergoing Noncardiac SurgeryChronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: The EUCLID trialEvaluation of clinical outcomes among nonvalvular atrial fibrillation patients treated with rivaroxaban or warfarin, stratified by renal functionThe Reply
P50
Q27023569-67EB9E20-2759-4948-A93E-D8179C613B8CQ28081375-ABB2A94B-BB25-44C0-8CED-E936EBB897D8Q33600990-D2030334-436F-4FD0-A90B-5840FB38F163Q33646596-D141CE6F-618D-4865-B6D0-20995D9B4A3CQ34487399-348D5114-D1D2-4581-8769-D631DB5A6549Q37681981-2B404716-2D0E-4A91-874D-19C9742AFDBAQ38622500-97631B42-E059-4DAC-8BE3-3FFF1860EBFBQ38803492-621BD084-EAA9-41DF-B762-2D05BD116ADEQ39153219-7037B00B-DA2A-493A-A49B-39219C6F406EQ39941825-6AC475D5-CFFF-40C8-BAAC-CE26435F1D21Q40101721-914C92BA-3E09-4D17-80B2-C3FD988AEC02Q40195813-AEBA16D6-1829-47E5-84BD-03438312990DQ42180113-1F707218-D399-48E8-981B-E690736B10E9Q47231771-9F926C0E-0AF8-4437-B94A-2C72FABBFC10Q47377594-E64507A8-0042-4567-ACE3-1B3221C0E208Q47669541-242866E2-D0AD-4555-B242-89A2EFB9BDDEQ49395451-14155C25-B4B2-4261-9228-0A115B114FCAQ49972139-F5247AC9-101F-49F5-A664-3E7948BD3385Q50044497-23C6B9CB-4117-4C72-8BAA-49BC4D098A13Q90489550-B4B33EB4-3550-4ABD-8337-68D62F8E33F4Q91150846-9D12235D-4F0A-4E01-A66B-B8EE7A1B163DQ91684933-0F25DB3A-6C74-41AC-8AA0-0E1F842D5B3BQ92145005-78CD2452-99AB-4EC8-AB6A-B4EF38191468Q95432216-289BDC7A-892B-4A54-9EA8-EC8A25A965B0Q95517790-3F789CBF-45A4-434A-8AFE-349B7C1E720B
P50
description
researcher (ORCID 0000-0001-8216-4647)
@en
name
Jeffrey S Berger
@en
type
label
Jeffrey S Berger
@en
prefLabel
Jeffrey S Berger
@en
P31
P496
0000-0001-8216-4647